Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed NMUS starting to look tempting down here as a ZYNE sympathy play if nothing else- but as Vinpat has pointed out, there could be more dilution on the horizon. Definitely worth watching though! Did you ever get those shares?
ZYNE missed this again today, woke up early but couldn't bring myself to buy the $28.50 1st print gap up. Big mistake! Won't be buying anytime soon at this valuation... Congrats to those who did have brass balls!
Wow this garbage fell fast, pretty high grade WS scam going on here. Stock probably worth no more than 25 cents to be generous...
RVNC seems like they're pushing back RT001 trial results until 2016 now- damn talk about dead in the water, what's the holdup anyway? Manufacturing problems?
Buyer beware! Caveat emptor slapped on by OTCMarkets.
Not that you care anymore...
Damn man where was I, 3 days late to the party. :( Congrats to those that got in early!
IMUN thanks Rock Kicker for your ongoing excellent DD on this stock, hopefully the PPS doesn't fall apart too!
FTCY recently posted first quarterly profit ever.
Nice call, people would have been wise to heed your advice.
You have clearly failed to do your DD, so please don't waste people's time. All you have to do is look at the YOY comps to know that 2/3 of the annual sales take place in the second half of the year. And an entire 50% takes place in Q4. In addition, the IPO added a major boost to brand name recognition/increased sales and the last ER for Q2 only included 12 days of sales from after the IPO.
Thank you kindly sir!
Hi Z, I noticed you used to use profitspi to get your charts, what is that site you are using now if you don't mind me asking? It looks like the stock charts font but I've never seen that format before...
Dr. Stauffer buying in the open market today, first insider buy for this stock.
Hey bud I wouldn't be surprised at all, read this section from the prospectus, basically the underwriters will be in control for awhile. GLTY!
In order to facilitate this offering, persons participating in this offering may engage in transactions that stabilize, maintain, or otherwise affect the price of our common stock during and after this offering. Specifically, the underwriters may engage in the following activities in accordance with the rules of the Securities and Exchange Commission.
Short sales. Short sales involve the sales by the underwriters of a greater number of shares than they are required to purchase in the offering. Covered short sales are short sales made in an amount not greater than the underwriters’ option to purchase additional shares from us in this offering. The underwriters may close out any covered short position by either exercising their option to purchase shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option. Naked short sales are any short sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering.
Stabilizing transactions. The underwriters may make bids for or purchases of the shares for the purpose of pegging, fixing, or maintaining the price of the shares, so long as stabilizing bids do not exceed a specified maximum.
Penalty bids. If the underwriters purchase shares in the open market in a stabilizing transaction or syndicate covering transaction, they may reclaim a selling concession from the underwriters and selling group members who sold those shares as part of this offering. Stabilization and syndicate covering transactions may cause the price of the shares to be higher than it would be in the absence of these transactions. The imposition of a penalty bid might also have an effect on the price of the shares if it discourages resales of the shares.
The transactions above may occur on The NASDAQ Global Market or otherwise. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of the shares. If these transactions are commenced, they may be discontinued without notice at any time.
http://ih.advfn.com/p.php?pid=nmona&article=67958582
OMG iHUB what is up with this HUGE Scottrade ad taking up the entire right-hand half of the screen when viewing posts on a board!? Anybody else see it? You have to be out of your effing minds, please fix it stat! It is not worth driving away all your users for one ad!
Anemic volume, no more pump posts. Ahh ain't that a shame? Last one out hit the lights James Hetfield style! ;)
With this volume secondary could be done by today...
China's Great Short Seller Suddenly Turns Bullish
http://www.bloomberg.com/news/articles/2015-07-29/china-s-hated-short-seller-is-now-a-bull-predicting-huge-rally
Is it "Dan Zanger" or "Dan Lee"? Either way it is highly suspect that a multi-millionaire trader would need to resort to shilling a garbage trading product for $125 a month...
http://www.chartpattern.com/cf/registration_form.cfm
Nice commentary on the interconnection between analysts and bookrunners. Yes there was some lack of consideration for current shareholders- hell they have $42M in cash, did they really need to do this deal now? But this deal will make the company stronger in the long run.
Yes the price will probably fall and the gap will be filled with the 15% dilution but some of us are in this for the longterm and have held since the IPO. I think this is going much higher and I want to be able to take the longterm capital gains tax when my profits are 300-400% at least. In the mean time good luck trading this unpredictable stock.
Wow 18% of the float is short, could be setting up for a major squeeze before ER. This is undervalued with PEG ratio of only .22 (44 PE / 210% growth), insane!
Anyone shorting at this valuation should have their head examined- but of course the majority shorts are probably just hedging long positions, nobody would actually be dumb enough to natural short it right?
CARA secondary offering. :(
Total common stock to be outstanding after this offering:
26,018,514 shares, or 26,495,753 shares if the underwriters exercise their option to purchase additional shares in full, which in each case is based on an aggregate offering of $65,000,000 of our common stock at an assumed public offering price of $20.43 per share (the last reported sale price of our common stock on The NASDAQ Global Market on July 24, 2015).
Because it's a scam.
Interesting, any ideas about which tickers were involved?
AREN nice move, knew this would be a promo eventually...
Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic Pruritus
Novel peripheral kappa opioid I.V. CR845 achieved statistically-significant results on primary endpoint of reducing worst itch intensity
Trial demonstrated statistically significant results on secondary endpoint of quality of life improvements with additional positive trend on itch-related sleep disturbances
I.V. CR845 found to be safe and well-tolerated in dialysis patients
Conference call today at 8:30 a.m. ET to discuss results and next steps
SHELTON, Conn., July 23, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced statistically significant topline results from its Phase 2 trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus (UP). Uremic pruritus is a chronic systemic itch condition in patients with renal failure, often receiving hemodialysis. There are currently no approved products in the United States for the condition.
"These results demonstrate the potential of our lead candidate CR845 to address an additional indication of significant unmet need beyond our lead I.V. CR845 program in acute pain," said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "With this encouraging data, we plan to engage the FDA in a formal meeting to guide the structure of a potential Phase 3 pivotal trial, which we would expect to begin in 2016."
The Phase 2 trial was a double-blind, randomized, placebo-controlled trial designed to evaluate the efficacy of I.V. CR845 compared to placebo in reducing the intensity of itch in dialysis patients over a two-week dosing period. The trial enrolled 65 dialysis patients at multiple sites in the United States.
The primary endpoint of the Phase 2 trial was the change from baseline of the average worst itching during the second week of treatment, as recorded on a visual analog scale (VAS). Patients receiving I.V. CR845 experienced a 54 percent greater reduction in worst itch scores than those receiving placebo (p-value = 0.016), with an average reduction of -48 percent from baseline as measured by the VAS. I.V. CR845-treated patients exhibited statistically significant reductions in both daytime (-51 percent, p=0.03) and nighttime (-75 percent, p=0.007) worst itch scores compared to placebo treatment.
Secondary endpoints focused on quality of life measures associated with pruritus using a series of previously validated self-assessment scales, including the Skindex 10 score. Patients receiving I.V. CR845 experienced a 71 percent greater reduction in the average total Skindex 10 score at the end the two-week treatment period than those receiving placebo (p-value=0.031). The total score average included positive trends in patients receiving I.V. CR845 for each of the three Skindex 10 domains: disease, mood/emotional distress (statistically significant reduction, p-value = 0.046) and social functioning. Another secondary measure, itch-related sleep disturbances based on the Itch MOS Sleep Problems Index II, showed a positive trend in patients receiving I.V. CR845, with a 62 percent improvement compared to placebo, although this trend was not observed to be statistically significant.
I.V. CR845 was shown to be safe and well tolerated during the study with no CR845-related serious adverse events (AEs) reported. The most common AEs were transient numbness and dizziness, with no episodes of the CNS side effects (e.g., dysphoria and hallucinations) that have impeded the development of centrally-acting kappa opioids.
"The results of the CR845 Phase 2 study are very encouraging. The data demonstrate a robust effect of reducing both daytime and nocturnal itching by an objective scoring system as well as anecdotal quality of life histories," said Dr. James Tumlin, Professor, Department of Medicine, University of Tennessee and a Principal Investigator on the trial. "With no approved therapy and the limited efficacy of current options, CR845 provides an opportunity to alleviate the pain and discomfort of this persistent clinical problem among ESRD patients."
There are more than 400,000 patients in the United States and 2.2 million globally undergoing hemodialysis and it is estimated that as many as 50 percent of these patients suffer from renal or uremic pruritus. Currently, there are no approved products in the United States for the condition, which can often be severe and resistant to treatment with traditional itch treatments, such as corticosteroids and antihistamines.
"We are excited by these topline results in uremic pruritus, which show that I.V. CR845 holds significant clinical potential in this indication of significant unmet need for dialysis patients," said Joseph Stauffer, D.O., M.B.A., Chief Medical Officer of Cara Therapeutics. "I.V. CR845 demonstrated a statistically significant effect, not only on our primary endpoint of reducing the itch intensity for dialysis patients, but also in important quality of life measurements, along with a favorable safety and tolerability profile."
Conference Call
Cara management will host a conference call today at 8:30 a.m. ET to discuss the UP trial results and next steps for the program.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 93878802. A live webcast of the call can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About CR845
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was found to be safe and well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara expects to initiate its Phase 3 Program of I.V. CR845 for acute pain with a first adaptive pivotal trial in laparoscopic abdominal surgery in 3Q'15. In addition, a Phase 2 trial of CR845 in osteoarthritis patients using an oral tablet formulation is planned for 3Q'15.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the expected timing for meeting with the FDA regarding the results of the Company's Phase 2 trial of I.V. CR845 in in dialysis patients experiencing uremic pruritus, the potential for the advancement of I.V. CR845 to advance into a pivotal trial program, the potential future successful clinical and regulatory development of I.V. CR845 for uremic pruritus, and the expected timing of planned clinical trials for the Company's other development programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics' filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2014 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
http://ir.caratherapeutics.com//releasedetail.cfm?ReleaseID=923457
RBCC ditto on the chart but the trading action is somewhat telling. They aren't trying to hide their hand- constant gap ups on first print, one day's high is the next day's low etc. I'll be watching if more big blocks go off at the ask so as to continually increase (wash up) volume, thinking the guys running it may be getting ready to take profits...
Good post Lone Wolf I believe there is a whole lot more to this FIT than meets the eye, GLTY...
Wouldn't say it's a promo persay- can't find any info that supports that view. Not much going on in OTC land in these days. I think it could just be some washtrading. Volume doesn't seem high enough to be a boiler room play. Anyway it does have that look to it like it could be a promo but nothing much to support it.
RVBR gotta love the Russian mobster matches. Starting to think the .10 prints early June were a signal of things to come, any thoughts? Either way nice little home run from a penny- solo shot just barely cleared the wall!
Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics' CR845
BOONTON, N.J., July 14, 2015 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that it has entered into a new agreement for continued clinical testing with development partner Cara Therapeutics (Nasdaq: CARA) involving Cara's peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.
Cara's formulation of oral CR845 will continue to utilize Enteris' proprietary oral delivery technology under a renewed and revised Manufacturing and Clinical Supply Agreement. The new agreement includes technology access payments to Enteris and is representative of Enteris' broader "Feasibility-to-Licensing" strategy involving its peptide and small molecule oral drug delivery platform.
Brian Zietsman, President and CFO of Enteris BioPharma, commented: "We are pleased to be continuing our collaboration with Cara and with the progress of oral CR845. This collaboration and this new agreement showcase the value of Enteris' proprietary oral delivery technology to our strategic partners. The continuing clinical testing of oral CR845 is yet another validation of our oral drug delivery platform, which has been shown to be safe and well tolerated and has demonstrated clinically meaningful efficacy and enhanced bioavailability in Phase 2 and Phase 3 studies conducted by other partners."
Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics, remarked, "We continue to be very impressed with the bioavailability and bioactivity exhibited by the oral formulation of CR845 utilizing Enteris' proprietary technology, and we look forward to initiating our Phase 2 study in osteoarthritis in Q3 of this year. In our estimation, oral CR845 has the potential to address a significant market opportunity in the treatment of acute and chronic pain for which there continues to be a very large unmet need for safer, non-abusable alternatives to narcotic opioids and NSAIDs."
About Cara Therapeutics: Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
About Enteris BioPharma: Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. Enteris' proprietary oral delivery technology has demonstrated a track record of success across a range of compounds and therapeutic indications and has also been the subject of numerous feasibility studies and active development programs, of which several are in clinical development. For more information on Enteris BioPharma and its proprietary oral delivery technology.
Good luck with that maybe one day you can sell your shares to a greater fool, probably one who posts on this board...
Does not matter, as IENT being Form 15 filers, us shareholders won't ever gross dollar 1 of revenues unless it is merged into a reporting entity... For policy reasons the SEC has so far insurmountable threshold for companies that go PINK via a Form 15 filing which is an INTENTIONAL, EXPLICIT choice to spit in the face of the SEC and continue operating while telling the SEC to pound sand. Form 15 is a one-way ticket to the PINK side.
Come to think of it why not reverse-merge with MYGG? They are fully compliant and have similar games. It would make a lot of sense Bill, get this deal done for the sake of IENT shareholders who have been loyal to you for years!
Stealey really needs to reverse-merge IENT into a new shell if he wants this company to succeed. The SEC has an insuperably high threshold for any Form 15 filer to prove that their remedial disclosure of activities during the time they've gone dark are accurate and complete. From a policy standpoint, the SEC doesn't want companies to use Form 15 to go dark, commit malfeasance, and then say "we're done dumping now- let us back into compliance".
Until then few investors will touch this no matter what breakthroughs Stealey has been making with IENT. What's the point of investing in a company that refuses to open the books? C'mon Bill do the right thing for your investors! You spent all this money on making the new games but will never become SEC compliant? It makes no sense unless you're just looking to dump shares...
OMAG timmbbbeerr!
Lol whoops!
I'm hearing mixed things about Centerpoint Securities. Anyone have anything to share about them?